164 related articles for article (PubMed ID: 17410715)
1. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.
Spagnolo A; Glick RP; Lin H; Cohen EP; Feinstein DL; Lichtor T
J Neurosurg; 2007 Feb; 106(2):299-305. PubMed ID: 17410715
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
[TBL] [Abstract][Full Text] [Related]
3. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
[TBL] [Abstract][Full Text] [Related]
4. Immunogene therapy as a treatment for malignant brain tumors in young mice.
Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
Spagnolo A; Grant EN; Glick R; Lichtor T; Feinstein DL
Neurosci Lett; 2007 Apr; 417(1):72-7. PubMed ID: 17324516
[TBL] [Abstract][Full Text] [Related]
6. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
[TBL] [Abstract][Full Text] [Related]
7. The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model.
Grommes C; Karlo JC; Caprariello A; Blankenship D; Dechant A; Landreth GE
Cancer Chemother Pharmacol; 2013 Apr; 71(4):929-36. PubMed ID: 23358645
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells.
Lichtor T; Glick RP; Kim TS; Hand R; Cohen EP
J Neurosurg; 1995 Dec; 83(6):1038-44. PubMed ID: 7490618
[TBL] [Abstract][Full Text] [Related]
9. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice.
Deshmukh P; Glick RP; Lichtor T; Moser R; Cohen EP
J Neurosurg; 2001 Feb; 94(2):287-92. PubMed ID: 11213967
[TBL] [Abstract][Full Text] [Related]
10. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
11. The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.
Ching J; Amiridis S; Stylli SS; Bjorksten AR; Kountouri N; Zheng T; Paradiso L; Luwor RB; Morokoff AP; O'Brien TJ; Kaye AH
Oncotarget; 2015 Aug; 6(25):21301-14. PubMed ID: 26046374
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats.
Park SW; Yi JH; Miranpuri G; Satriotomo I; Bowen K; Resnick DK; Vemuganti R
J Pharmacol Exp Ther; 2007 Mar; 320(3):1002-12. PubMed ID: 17167171
[TBL] [Abstract][Full Text] [Related]
13. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.
Glick RP; Lichtor T; Panchal R; Mahendra A; Cohen EP
J Neurooncol; 2003; 64(1-2):139-46. PubMed ID: 12952294
[TBL] [Abstract][Full Text] [Related]
14. PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.
Papi A; Tatenhorst L; Terwel D; Hermes M; Kummer MP; Orlandi M; Heneka MT
J Neurochem; 2009 Jun; 109(6):1779-90. PubMed ID: 19457135
[TBL] [Abstract][Full Text] [Related]
15. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.
Glick RP; Lichtor T; Kim TS; Ilangovan S; Cohen EP
Neurosurgery; 1995 Mar; 36(3):548-55. PubMed ID: 7753355
[TBL] [Abstract][Full Text] [Related]
16. Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system.
Griffitt W; Glick RP; Lichtor T; Cohen EP
Neurosurgery; 1998 Feb; 42(2):335-40. PubMed ID: 9482184
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis.
Okunuki Y; Usui Y; Nakagawa H; Tajima K; Matsuda R; Ueda S; Hattori T; Kezuka T; Goto H
Exp Eye Res; 2013 Nov; 116():291-7. PubMed ID: 24107513
[TBL] [Abstract][Full Text] [Related]
18. Cytokine immuno-gene therapy for treatment of brain tumors.
Lichtor T; Glick RP
J Neurooncol; 2003 Dec; 65(3):247-59. PubMed ID: 14682375
[TBL] [Abstract][Full Text] [Related]
19. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Hau P; Kunz-Schughart L; Bogdahn U; Baumgart U; Hirschmann B; Weimann E; Muhleisen H; Ruemmele P; Steinbrecher A; Reichle A
Oncology; 2007; 73(1-2):21-5. PubMed ID: 18332649
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion.
Wan Z; Shi W; Shao B; Shi J; Shen A; Ma Y; Chen J; Lan Q
Mol Cell Biochem; 2011 Mar; 349(1-2):1-10. PubMed ID: 21221726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
